IPX Stock Analysis: IperionX American | NASDAQ
Other Industrial Metals & Mining | NASDAQ, USA | Market Cap: 609m USD | 12M Return: -68.3% | US44916E1001 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.72M
Warnings
Tailwinds
No distinct edge detected
Seasonality 4.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
IperionX Limited (NASDAQ: IPX) is a U.S.-based materials company focused on developing critical mineral resources and titanium metal powder production. The company holds 100% interest in the Titan Project in Tennessee, which contains titanium, zircon, and rare earth mineral resources.
In addition to mineral property development, IperionX produces angular and spherical titanium metal powders, targeting end markets including automotive and transport, consumer electronics, aerospace and defense, energy, medical, luxury goods, and industrial sectors. Titanium metal powders are widely used in additive manufacturing (3D printing), where they serve as feedstock for producing lightweight, high-strength components for aerospace, defense, and medical implant applications.
The company was incorporated in 2017, originally under the name Hyperion Metals Limited before rebranding to IperionX Limited in February 2022. It is headquartered in Charlotte, North Carolina, and trades on NASDAQ as an American Depositary Share following its June 2022 listing.
- Titanium powder offtake agreements expand with aerospace and defense customers
- US critical minerals grants accelerate Titan project development timeline
- Rare earth and zircon byproduct sales begin generating initial revenues
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.99 > 0.02 and ΔFCF/TA -49.71 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.43 > 3% & CFO -45.2m > Net Income -137.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (3.39m) vs 12m ago 965.5% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -42.67 > 6 (EBIT TTM -148.4m / Interest Expense TTM 3.48m) |
| A: 0.29 (Total Current Assets 44.0m - Total Current Liabilities 13.6m) / Total Assets 105.8m |
| B: -1.66 (Retained Earnings -176.0m / Total Assets 105.8m) |
| C: -1.41 (EBIT TTM -148.4m / Avg Total Assets 105.4m) |
| D: 5.06 (Book Value of Equity 88.3m / Total Liabilities 17.5m) |
| Altman-Z'' = -7.69 = D |
As of October 04, 2026, the stock is trading at USD 16.97 with a total of 263,684 shares traded. Over the past week, the price has changed by -13.46%, over one month by -20.44%, over three months by -41.04% and over the past year by -68.33%.
Current recommended Stop Loss: 15.30 (which is 9.8% or 1.3 ATR below the current price).
IperionX American has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy IPX.
- StrongBuy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 42.5 | 150.4% |
P/E Forward = 1250.0
P/B = 7.2024
Revenue TTM = 0.0 USD
EBIT TTM = -148.4m USD
EBITDA TTM = -141.1m USD
Long Term Debt = 9.39k USD (from longTermDebt, two quarters ago)
Short Term Debt = 629k USD (from shortTermDebt, last quarter)
Debt = 7.89m USD (from shortLongTermDebtTotal, last quarter) + Leases 3.73m
Net Debt = -27.4m USD (calculated: Debt 7.89m - CCE 35.2m)
Enterprise Value = 581.9m USD (609.3m + Debt 7.89m - CCE 35.2m)
Interest Coverage Ratio = -42.67 (Ebit TTM -148.4m / Interest Expense TTM 3.48m)
EV/FCF = -5.57x (Enterprise Value 581.9m / FCF TTM -104.5m)
FCF Yield = -17.95% (FCF TTM -104.5m / Enterprise Value 581.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 5.82m) / Revenue TTM)
Tobins Q-Ratio = 5.50 (Enterprise Value 581.9m / Total Assets 105.8m)
Interest Expense / Debt = 44.05% (Interest Expense 3.48m / Debt 7.89m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -117.2m (EBIT -148.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.24 (Total Current Assets 44.0m / Total Current Liabilities 13.6m)
Debt / Equity = 0.09 (Debt 7.89m / totalStockholderEquity, last quarter 88.3m)
Debt / EBITDA = 0.19 (negative EBITDA) (Net Debt -27.4m / EBITDA -141.1m)
Debt / FCF = 0.26 (negative FCF - burning cash) (Net Debt -27.4m / FCF TTM -104.5m)
Total Stockholder Equity = 95.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -130.6% (out of range, set to none)
RoE = -144.3% (Net Income TTM -137.6m / Total Stockholder Equity 95.3m)
RoCE = -155.6% (out of range, set to none) (EBIT -148.4m / Capital Employed (Equity 95.3m + L.T.Debt 9.39k))
RoIC = -126.3% (out of range, set to none) (NOPAT -117.2m / Invested Capital 92.8m)
WACC = 14.71% (E(609.3m)/V(617.2m) * Re(14.45%) + D(7.89m)/V(617.2m) * Rd(44.05%) * (1-Tc(0.21)))
Discount Rate = 14.45% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: -42.75 | Cagr: -55.51%
[DCF] Fair Price = unknown (Cash Flow -104.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.83 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.33 | Chg30d=+0.00% | Revisions=+0% | Analysts=1
EPS next Quarter (2026-12-31): EPS=-0.29 | Chg30d=+0.00% | Revisions=+0% | Analysts=1
EPS current Year (2026-06-30): EPS=-1.86 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=-1450.0% | GrowthRev=+0.0%
EPS next Year (2027-06-30): EPS=-1.02 | Chg30d=-45.74% | Revisions=+25% | GrowthEPS=+48.8% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +25% (up=1, down=0)